BridgeBio Pharma
BBIO
304 hedge funds and large institutions have $6.45B invested in BridgeBio Pharma in 2025 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 121 increasing their positions, 79 reducing their positions, and 29 closing their positions.
489% more call options, than puts
Call options by funds: $472M | Put options by funds: $80.1M
152% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 29
53% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 79
33% more capital invested
Capital invested by funds: $4.85B → $6.45B (+$1.6B)
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
16% more funds holding
Funds holding: 263 → 304 (+41)
4.54% more ownership
Funds ownership: 93.48% → 98.02% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$76.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$66.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$56.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$51.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$50.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$202M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$103M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$28.1M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$25.8M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$25.7M |
BBIO Hedge Fund Activity: Q1 2025 in Review
304 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2025, worth a combined $6.45B — up 33% from $4.85B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new BBIO positions and 29 closed out — a net gain of 44 holders — while 121 added to existing stakes and 79 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $76.3M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $202M.
- 304 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2025, up from 263 in Q4 2024.
- Funds reported $6.45B of BridgeBio Pharma stock for Q1 2025, up 33% quarter-over-quarter.
- 73 funds opened new BridgeBio Pharma positions in Q1 2025 and 29 closed out, a net change of +44 holders.
- The largest BridgeBio Pharma buyer in Q1 2025 was Janus Henderson Group, an estimated $76.3M added.
- The largest BridgeBio Pharma seller in Q1 2025 was Kohlberg Kravis Roberts & Co, an estimated $202M sold.
Based on aggregated 13F filings for Q1 2025.